Evidence map›Paper›PMID 31362988›Full record

ArticleThe Journal of biological chemistry2019

Regulation of PLPP3 gene expression by NF-κB family transcription factors.

Guogen Mao, Susan S Smyth, Andrew J Morris

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Bioactive lipids and metabolic syndrome-a symposium report.Annals of the New York Academy of Sciences · 2022
    Article
  12. Article
  13. Study on the Correlation Between NF-κB and Central Fatigue.Journal of molecular neuroscience : MN · 2021
    Review
  14. Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease.International journal of molecular sciences · 2021
    Review
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Guogen MaoDivision of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky College of Medicine, Lexington, Kentucky 40536.
Susan S SmythDivision of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky College of Medicine, Lexington, Kentucky 40536.
Andrew J MorrisDivision of Cardiovascular Medicine, Gill Heart and Vascular Institute, University of Kentucky College of Medicine, Lexington, Kentucky 40536 a.j.morris@uky.edu.
Lexington VA Health Care System · USUniversity of Kentucky · US

Funding

Lipid phosphate phosphatase 3 as a novel atherosclerosis suppressorR01HL120507 · NHLBI · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J, SMYTH, SUSAN S. · 2015 to 2018
$2.1M
Association of a common variant of the PPAP2B gene with cardiovascular disease.I01BX001984 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI MORRIS, ANDREW J · 2013 to 2016
–
Adipose autotaxin: a novel link between obesity and cardiovascular diseaseI01BX002769 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI SMYTH, SUSAN S. · 2015 to 2018
–
Lysophosphatidic acid and cardiovascular disease riskI01CX001550 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI MORRIS, ANDREW J · 2017 to 2021
–
Acquisition of an HPLC Electrospray/chemical ionization triple quadrupole linear ion trap mass spectrometer system.IS1BX003153 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI MORRIS, ANDREW J · 2015 to 2015
–
BLRD VA I01 BX001984BLRD VA I01 BX002769BLRD VA IS1 BX003153CSRD VA I01 CX001550NHLBI NIH HHS R01 HL120507
6 · The paper itself

Abstract

Lipid phosphate phosphatase 3 (LPP3), encoded by the PLPP3 gene, is an integral membrane enzyme that dephosphorylates phosphate esters of glycero- and sphingophospholipids. Cell surface LPP3 can terminate the signaling actions of bioactive lysophosphatidic acid (LPA) and sphingosine 1 phosphate, which likely explains its role in developmental angiogenesis, vascular injury responses, and cell migration. Heritable variants in the final intron PLPP3 associate with interindividual variability in coronary artery disease risk that may result from disruption of enhancer sequences that normally act in

Indexed as

Gene Expression RegulationHumansI-kappa B ProteinsLysophospholipidsNF-kappa BNF-kappa B p50 SubunitPhosphatidate PhosphatasePhosphatidylinositol 3-KinasesPromoter Regions, GeneticSignal TransductionSphingolipidsSphingosineTHP-1 CellsTranscription Factor RelATranscription Factor RelBTranscription FactorsI-kappa B Proteinslipid phosphate phosphataseLysophospholipidsNF-kappa BNF-kappa B p50 SubunitPhosphatidate PhosphatasePhosphatidylinositol 3-KinasesPLPP3 protein, humanRELA protein, humanRELB protein, humanSphingolipidsSphingosinesphingosine 1-phosphateTranscription Factor RelATranscription Factor RelBTranscription Factorsglycerophospholipidglycerosphingolipidlysophospholipidphosphatasetranscription promoter

Identifiers

PMID31362988
PMCPMC6755815
OpenAlexW2965081826

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.